Prostate cancer is a common malignancy in men, but its management is fraught with controversy owing to its variable biologic and clinical behavior. Despite evidence that PSA screening reduces prostate cancer specific metastasis and death, it has not gained acceptance by various health authorities. Nevertheless, recent advances in biomarker development potentially address many of the shortcomings of routine PSA testing alone, including improved specificity for the detection of clinically significant cancer, optimized risk stratification to aid clinical management decisions, and discovery of genetic variants that may guide optimized therapy of advanced disease.
Scandinavian journal of clinical and laboratory investigation. 2016 Aug 17 [Epub]
Robert E Reiter
a Bing Professor of Urologic Research, Department of Urology , Institute of Urologic Oncology, Geffen School of Medicine at UCLA , Los Angeles , CA , USA.